KWM
GYRE icon

Keebeck Wealth Management’s Gyre Therapeutics GYRE Stock Holding History

Keebeck Wealth Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,333
Closed -$7.03K – 261
2023
Q2 		$7.03K Hold
1,333
– – ﹤0.01% 260
2023
Q1 		$4.14K Sell
1,333
-1,334
-50% -$5.07K ﹤0.01% 249
2022
Q4 		$10.6K Buy
+2,667
New +$10.9K ﹤0.01% 238

Other funds holding GYRE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Keebeck Wealth Management's GYRE Position: Q3 2023 in Review

Keebeck Wealth Management sold out of Gyre Therapeutics (GYRE) in Q3 2023, closing a stake of 1,333 shares — an estimated $7.03K sold.

Keebeck Wealth Management first reported a position in GYRE in Q4 2022 and held it in 3 quarters. The position peaked at $10.6K in Q4 2022. 31 funds tracked by Wall St. Rank hold GYRE as of Q3 2023.

  • Keebeck Wealth Management reported no remaining Gyre Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Keebeck Wealth Management sold 1,333 Gyre Therapeutics shares in Q3 2023, an estimated $7.03K.
  • Keebeck Wealth Management first reported a position in Gyre Therapeutics in Q4 2022 and held it in 3 quarters.
  • Keebeck Wealth Management's Gyre Therapeutics position peaked at $10.6K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2023.

Based on Keebeck Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.